Bacterial type III "effector" proteins are the primary virulence factors that guide the progression of numerous Gram-negative bacterial infectious diseases. Recent studies have estimated that a single pathogen delivers 10-50 unique effector proteins directly into host cells. Collectively, these virulence factors hijack host innate immune response and facilitate bacterial replication, dissemination, and disease progression. Therefore, determining how bacterial effector proteins control host intracellular communication pathways at the structural, biochemical, and biophysical level is an ongoing challenge in infectious disease research. This proposal seeks to reveal a structural and functional understanding of these host-pathogen relationships. Prior to this proposal, we identified a class of Enterohaemorhagic E. coli effector proteins that directly regulates host membrane trafficking GTPases and a cell polarity kinases through unique structural interactions. Using these structures as a guide, we will determine the molecular mechanism for bacterial regulation of human signaling enzymes. This includes determining how bacteria hijack host cargo trafficking pathways by directly regulating ARF GTPase activity on a membrane surface (Aim 1). We will also examine a novel PAK kinase activation mechanism through a series of X-ray crystallography, small molecule inhibitor studies, and enzymatic assays (Aim 2). The resulting structure-based theories will be used to directly compare the actions of numerous bacterial type III effector homologs to assemble host enzymes into new signaling circuits on the surface of bacterial effector scaffolds (Aim 3). Developing new drugs that target bacterial effector - host enzyme complexes would be an innovative approach to combat emerging infectious disease. While this idea holds great potential, the paucity of mechanistic information gleaned from virulence factor structures has so far hampered their development as suitable drug targets. As a means to this end, these studies will allow us to predict new mechanisms of action for understudied bacterial effector proteins, and provide a glimpse into the structural-based evolutionary progression of a related pathogen group.

Public Health Relevance

Human kinases and GTPases are major targets of bacterial toxins and effector proteins. This proposal examines the ability of a family of bacterial type III effector proteins to hijack human signaling enzymes. A deeper understanding of the enzymatic and biochemical interface between these bacterial effectors and human kinases and GTPases by X-ray crystallography will lead to a more complete knowledge of numerous pathogenic mechanisms and may reveal new aspects of signal transduction in the human host cell.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
1R01GM100486-01A1
Application #
8235694
Study Section
Macromolecular Structure and Function B Study Section (MSFB)
Program Officer
Flicker, Paula F
Project Start
2012-02-01
Project End
2015-12-31
Budget Start
2012-02-01
Budget End
2012-12-31
Support Year
1
Fiscal Year
2012
Total Cost
$301,496
Indirect Cost
$111,496
Name
University of Texas Sw Medical Center Dallas
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Selyunin, Andrey S; Reddick, Lovett Evan; Weigele, Bethany A et al. (2014) Selective protection of an ARF1-GTP signaling axis by a bacterial scaffold induces bidirectional trafficking arrest. Cell Rep 6:878-91
Glotfelty, Lila G; Zahs, Anita; Hodges, Kimberley et al. (2014) Enteropathogenic E. coli effectors EspG1/G2 disrupt microtubules, contribute to tight junction perturbation and inhibit restoration. Cell Microbiol 16:1767-83
Reddick, L Evan; Alto, Neal M (2014) Bacteria fighting back: how pathogens target and subvert the host innate immune system. Mol Cell 54:321-8
Burnaevskiy, Nikolay; Fox, Thomas G; Plymire, Daniel A et al. (2013) Proteolytic elimination of N-myristoyl modifications by the Shigella virulence factor IpaJ. Nature 496:106-9